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Pulmonary surfactant is a substance composed of a lipoprotein complex that is essential to pulmonary function. Pulmonary
surfactant proteins play an important role in the structure, function, and metabolism of surfactant; 4 specific surfactant proteins
have been identified: surfactant proteins-A, surfactant proteins-B, surfactant proteins-C, and surfactant proteins-D. Clinical,
epidemiological, and biochemical evidence suggests that the etiology of respiratory distress syndrome is multifactorial with a
significant genetic component. There are reports about polymorphisms and mutations on the surfactant protein genes, especially
surfactant proteins-B, that may be associated with respiratory distress syndrome, acute respiratory distress syndrome, and congenital
alveolar proteinosis. Individual differences regarding respiratory distress syndrome and acute respiratory distress syndrome as
well as patient response to therapy might reflect phenotypic diversity due to genetic variation, in part. The study of the differences
between the allelic variants of the surfactant protein genes can contribute to the understanding of individual susceptibility to the
development of several pulmonary diseases. The identification of the polymorphisms and mutations that are indeed important for
the pathogenesis of the diseases related to surfactant protein dysfunction, leading to the possibility of genotyping individuals at
increased risk, constitutes a new research field. In the future, findings in these endeavors may enable more effective genetic
counseling as well as the development of prophylactic and therapeutic strategies that would provide a real impact on the management
of newborns with respiratory distress syndrome and other pulmonary diseases.
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INTRODUCTION
Pulmonary surfactant is a substance composed of a li-
poprotein complex that is essential to normal pulmonary
function; it is responsible for the decrease in superficial ten-
sion of the alveolar air-liquid interface, therefore prevent-
ing pulmonary collapse on expiration.1
In 1959, Avery and Mead suggested that surfactant de-
ficiency could cause hyaline membrane disease, currently
called respiratory distress syndrome (RDS).1 The inability
of the preterm newborns to produce adequate quantities of
surfactant due to pulmonary immaturity constitutes the pri-
mary etiology of respiratory distress syndrome (RDS).2
Decreased function of the surfactant also contributes to
the physiopathology of acute respiratory distress syndrome
(ARDS),3 characterized by acute pulmonary lesion with
pulmonary edema, nonhydrostatic and severe hypoxemia,
and high mortality rates of 10% and 90% (average, 50%),
depending on the etiological factor.
Respiratory distress syndrome constitutes one of the
main causes of respiratory morbidity and mortality in chil-
dren under 1 year of age.4 Despite the improvement in
neonatal survival rates, a high percentage (5%-25%) of
newborns affected by RDS will develop chronic pulmonary
disease.
High pulmonary morbidity has been attributed to tox-
icity by oxygen, barotrauma, immaturity in development,
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and nutritional deficiencies in these newborns. However,
significant differences in the evolution of the pulmonary
condition of newborn carriers of RDS having similar clini-
cal characteristics and comparable risk factors (for exam-
ple, the need for oxygen and mechanical ventilation), sug-
gest that other factors, such as genetics, can also contrib-
ute to these different clinical evolutions.5,6
The surfactant system
The surfactant complex comprises lipids (90%) and pro-
teins (10%). Among the lipids, about 70% is phospha-
tidylcholine predominating as dipalmitoylphosphatidyl-
choline. The second most important phospholipid compo-
nent is phosphatidylglycerol (10%); other phospholipids are
phosphatidylinositol, phosphatidylethanolamine, and
phosphatidylserine (Figure 1).
The surfactant proteins (SP) play an important role in the
structure, function, and metabolism of the surfactant. Four
specific proteins have so far been described: SP-A, SP-B,
SP-C, and SP-D. These proteins are synthesized and secreted
by type II epithelial cells and are classified into 2 groups:
the hydrophilic (SP-A and SP-D) and the hydrophobic (SP-
B and SP-C).7 Although the protein concentration of sur-
factant is significantly less than that of the phospholipids,
the surfactant proteins are fundamentally important for the
prevention of alveolar collapse.8 The surfactant proteins are
already well characterized regarding the genome, amino acid
composition, and messenger RNA (mRNA) sequence.9
There are two functional genes for SP-A (SP-A1 and
SP-A2) and one pseudogene,11 all being necessary for a
well-functioning, mature, and stable SP-A.12 The gene re-
sponsible for its production is located on the long arm of
chromosome 10.13 It is the most abundant protein, compris-
ing 5% of the surfactant composition.14 SP-A is hydrophilic,
a member of the collectin family, and presents recognition
domains for collagen and carbohydrates that relate to pul-
monary defense and pulmonary inflammatory processes.15
The de novo synthesis of SP-A occurs in a continuous and
independent manner from the lamellar bodies and other sur-
factant components.16 Once in the aerial space, SP-A as-
sociates with lipids, forming tubular myelin, a structural
form of the surfactant. In the mature lung, SP-A is ex-
pressed predominantly in type II epithelial cells and Clara
cells, and it is also expressed in tracheal gland cells.10
SP-B is a hydrophobic protein and constitutes 2% of
the surfactant composition.17 The locus of the gene respon-
sible for the production of SP-B is on the short arm of the
chromosome 2 (2p12→p11.2), extends for approximately
9.5 kilobases, and contains 11 exons.18 It is secreted by type
II epit helial cells and is essential for pulmonary function,
since it promotes the adsorption and distribution of the
phospholipids on a single layer, which corresponds to the
functional form of the surfactant.19 SP-B and SP-A are es-
sential for the formation in vitro of the tubular myelin, the
morphologic form of the surfactant. A well-structured tu-
bular myelin was found to be absent in newborns who died
due to RDS.20
                                        * DPPC –Dipalmitoylphosphatidylcholine
Figure 1 - Composition of surfactant. Modified from Jobe et al10
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Deficiency in SP-B is associated with an alteration of
production in normal lamellar bodies, blocking surfactant
secretion—not to the processing of active SP-C—leading
to a progressive respiratory insufficiency that is incompat-
ible with life.21
SP-C is a hydrophobic protein, constituting about 1%
of the surfactant composition.22 SP-C is expressed in type
II epithelial cells, processed in multivesicular bodies to its
mature form, stored in the lamellar bodies, and secreted
with SP-B and lipids.17 It has similar functions to those of
SP-B, ie, promoting the adsorption of phospholipids. Con-
trary to the case with SP-B, mice that do not produce SP-
C process SP-B normally and survive with no apparent pul-
monary disease.23 However, in humans, SP-C deficiency can
lead to pulmonary interstitial disease on the first years of
life. Experimental models demonstrate that tumor necro-
sis factor-alpha and viral infections lead to the decrease of
SP-C mRNA, which seems to lower the surfactant func-
tion.25,26
SP-D is a hydrophilic protein and has structural and
functioning similarities with SP-A. It constitutes 1% of the
surfactant composition and is a member of the collectin
family. In the lungs, SP-D is expressed by type II epithe-
lial cells, Clara cells, and other cells and glands. The ma-
jor part of SP-D is not associated with lipids.10 SP-D is re-
lated to pulmonary defense, but contrary to the case with
SP-A, it increases in the presence of acute pulmonary le-
sion. Rats that do not produce SP-D possess an increased
pool of lipids in the tissues and alveolus without an increase
of the surfactant proteins; these rats develop emphy-
sema.27,28 Congenital SP-D deficiency has so far not been
reported in humans.
Surfactant metabolism
Dipalmitoylphosphatidylcholine is synthesized on the
rough endoplasmic reticulum and transferred to the lamel-
lar bodies together with SP-B and SP-C (Figure 2). The la-
mellar bodies are the storage and secreting granules and
are surrounded by a limiting membrane that fuses with the
plasma membrane. Surfactant secretion can be stimulated
by the stretching of the type II epithelial cells, by the ac-
tion of beta-agonists, and purinergic agonists, such as ATP.29
After secretion to the interior of the alveolus, the sur-
factant goes through a complex cycle. The fat and protein
molecules form the tubular myelin. With the successive
movements of contraction and stretching that occur at each
respiratory cycle, part of the myelin becomes disorganized
and disassociates from the main film, forming small vesi-
cles that are reabsorbed to the interior of type II epithelial
cells. Inside the cell, a small portion is catabolized, whereas
most of the reabsorbed surfactant is reorganized on the la-
mellar bodies in a recycling process. In preterm newborns,
50% of the alveolar pool is composed of inactive vesicles
that will be recycled. This relationship is more unfavorable
in conditions of pulmonary lesion, such as in RDS cases.10
Figure 2 - Surfactant intracellular metabolism. Modified from Whitsett et al30
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Surfactant proteins: genetic determinants and
pulmonary diseases
The importance of SP-B for the function of the sur-
factant is clearly exemplified by the results of studies us-
ing “knock-out” mice for the SP-B gene, that is, mice in
which the gene responsible for the production of SP-B has
been experimentally removed. Despite the fact that lungs
of SP-B (-/-) mice develop normally, they are atelectatic
at birth, and the mouse dies due to acute respiratory insuf-
ficiency. On the other hand, heterozygous mice (+/-) do not
present early respiratory insufficiency.31 Heterozygous mice
present reduced pulmonary compliance and increased pul-
monary residual volume; therefore, their lungs are vulner-
able to pulmonary lesion, and they develop respiratory fail-
ure when submitted to hyperoxia.32,33
Some descriptions about the presence of polymorphisms
and mutations in genes from the surfactant components are
reported in the literature, particularly regarding the SP-B
gene, which seems to be associated with RDS, ARDS, and
CAP.34-40
The inability to produce SP-B is the result of an
autosomic recessive disease that leads to a fatal respiratory
insufficiency, congenital alveolar proteinosis (CAP), indi-
cating the fundamental role this protein plays in normal
pulmonary function.41
In 1994, Nogee et al42 demonstrated the existence of a
mutation-type frameshift, consisting of the substitution of
a nucleotide sequence, GAA, with a single nucleotide, C,
on codon 121 of the gene responsible for the production
of SP-B. In the index family studied by the authors, 3 term
newborn babies developed fatal respiratory insufficiency,
while the parents and 3 siblings did not present any respi-
ratory symptoms, suggesting a recessive autosomic inher-
itance pattern. SP-B was not detected in the pulmonary tis-
sue of the children with the disease, and SP-B mRNA was
not detected by the Northern blot method.41,42 The authors
concluded that this mutation could be responsible for SP-
B deficiency and for CAP, and they suggested that the dis-
ease could have a higher incidence than that reported by
them previously in 1993.
In 1998Lin et al,43 identified 3 mutations (2 substitu-
tions and 1 deletion) on the gene of protein B from the sur-
factant of 3 individuals with a CAP diagnosis from the same
family.43 The most important was the mutation 122delT,
which resulted in an anomalous and nonfunctioning SP-B;
a “hot-spot” (presence of 3 mutations in a small region of
the gene) was identified on exon 4 of the SP-B gene. The
authors also suggested the possibility of mutations respon-
sible for CAP or other respiratory diseases occurring in a
region near the “hot-spot” described in this study.
After 2 years, Lin et al published a study of a family
with a history of 14 newborn deaths due to early respira-
tory insufficiency.44 The immunohistochemistry of the lung
from 3 of these children showed a decrease or absence of
SP-B expression. Nine polymorphisms were found in this
family, but it was not possible to attribute any of them to
the SP-B deficiency. The analysis of the mRNA using RT-
PCR (reverse transcript polymerase chain reaction) of pul-
monary tissues embedded in paraffin from patients with
CAP demonstrated that the mRNA of SP-B showed altera-
tions. The authors concluded that the CAP problem in this
family could reflect aberrations on the mRNA of the B pro-
tein of the surfactant. Nogee et al described 13 new muta-
tions on the gene from SP-B responsible for SP-B defi-
ciency, indicating a high level of allelic and biochemical
heterozygosis regarding CAP.37
Newborns with hereditary SP-B deficiency are usually
full-term infants who develop respiratory insufficiency dur-
ing the first hours of life. The clinical condition is similar
to that of preterm newborns with RDS. However, despite
the treatment with surfactant, mechanical ventilation, and
extracorporeal membrane oxygenation (ECMO), these ba-
bies usually die in the first months of life due to respira-
tory insufficiency. Immunohistochemistry shows an absence
of proSP-B and SP-B, and the definitive diagnosis is
achieved through DNA sequencing, showing the presence
of the mutation of complementary DNA (cDNA) of the af-
fected individuals and relatives. More than 25 distinct mu-
tations in the SP-B gene have been identified, and all of
them have a recessive autosomic genotype.37 The most fre-
quent mutation of SP-B deficiency is 121ins2; its frequency
is 1 for each 1000 to 3000 individuals.41,45
Deficiency in SP-C is associated with severe lung dis-
ease in neonates, and most mutations in the SP-C gene are
inherited as a dominant gene. Various mutations on the SP-
C gene have been described in infants with RDS and se-
vere chronic lung disease, and in nonspecific interstitial
pulmonary pneumonitis, interstitial pulmonary fibrosis, and
interstitial fibrosis in older individuals. The age and pathol-
ogy presentation are variable, and the pathological findings
depend on age, clinical progression, and presence of in-
fections.6,24,46
Recently, mutations of the transport protein ABCA3
have been associated with respiratory failure in full-term
newborns, with a recessive autosomic inheritance. The pro-
tein ABCA3 is a member of the ATP-dependent transporter
family, as is the cystic fibrosis transmembrane conductance
regulator and multiple-drug-resistant protein known for
transporting a variety of ligands, ions, proteins, peptides,
carbohydrates, and lipids.47
The transporting protein ABCA3 has been identified in
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the membrane that limits the lamellar bodies, and it is ex-
pressed in the lung epithelial cells.48 Newborns with a de-
ficiency of this protein develop respiratory failure during
the first 24 hours of life that is refractory to the use of sur-
factant and ventilation. Chest radiography can detect sur-
factant deficiency, which is revealed by a ground-glass pat-
tern. The pulmonary pathology is compatible with alveo-
lar proteinosis and desquamating interstitial pneumonia.
In cases of ABCA3 deficiency, electronic microscopy
shows structural alterations of small lamellar bodies, with
densely colored inclusions.47 Tubular myelin is absent, and
the airspaces are filled with macrophages, lipid, and pro-
tein debris. It has been suggested that ABCA3 deficiency
causes abnormalities in surfactant conditioning, secretion,
and function, leading to respiratory failure. It has been re-
cently demonstrated that patients with mutations on
ABCA3 present surfactant with phosphatidylcholine defi-
ciency and altered function.49 Despite the fact that the
prevalence of mutations of ABCA3 has not yet been de-
termined, such pathology is more frequent than deficien-
cies of SP-B and SP-C, and it can also contribute to fam-
ily lung interstitial disease in adults and children.
Genetic factors of respiratory distress syndrome
Clinical, epidemiological, and biochemical evidence
suggests that the etiology of RDS is multifactorial, with a
significant genetic component.6,34 Prematurity is one of the
most important predisposing factors of the RDS etiology;
it is rare in full-term newborns.6,34 The male gender con-
stitutes a risk factor for the development of RDS.51,52 Black
preterm newborns present a lower and less severe incidence
of the disease than white newborns.51,53 Figure 3 a the sche-
matic representation of environmental and genetic factors
and the interaction between these and the RDS phenotype.
Due to the importance of the surfactant proteins on the
biology and physiology of the surfactant, various authors
have suggested that under certain circumstances these pro-
teins are factors that can contribute to the etiopathogenesis
of RDS.34,36 The authors have demonstrated that there is a
positive synergism between one SP-A allele and a poly-
morphic variant of SP-B and RDS. Other authors had pre-
viously described that certain polymorphisms of SP-B oc-
cur at a high frequency in a group of patients who are RDS
carriers.35
Individual differences related to RDS and the patient’s
response to the treatment can reflect phenotypic diversity,
due partially to genetic variation.
Some genes seem to be involved in the pathogenesis
of RDS, with the genes for SP-A and SP-B being the most
studied ones. This is due to the direct importance of these
proteins to surfactant biology and to the development of
RDS. Recently, most studies have reported the importance
of the interaction between SP-A and SP-B regarding
genotyping analysis in newborns with RDS. This interac-
tion could be responsible for the determination of a higher
or lower risk of developing RDS.
The SP-C gene has various polymorphic sites in differ-
ent locations. Association between this gene and RDS can-
not be ruled out.7,54,55 Although the knock-out mouse for the
SP-C gene is viable and grows normally without signifi-
cant alterations, the lungs have reduced compliance.23
Abnormalities observed on the knock-out mouse for the
SP-D gene, as well as the increase in the alveolar phos-
pholipid pool, suggest that SP-D could be more important
than previously thought.27,28 However, there is no evidence
so far indicating that allelic variations can be attributed or
not to RDS.
The genes that codify the surfactant proteins A, B, C
,and D contain various polymorphisms on their nucleotide
sequences. Many of these variations are polymorphisms of
a single nucleotide (single nucleotide polymorphism—
SNPs), which result from substitutions of amino acids or
silent modifications, whereas others are located on the
introns or on 5’ UTR or 3’ UTR regions and do not cause
alterations in the codified peptide sequence, but they can
affect the level of transcription or posttranscription.6
The study of the differences between the allelic vari-
ants of the surfactant protein genes can help explain indi-
vidual variability regarding susceptibility for the develop-
ment of various pulmonary diseases. SP-B is one of the
most important components of the surfactant system, and
various studies have showed this relationship.
Floros et al, in 2001,56 genotyped individuals with and
without RDS for variants of intron 4 and for 4
polymorphisms of SP-B: AC-18, AC-1013, CT-1580, and
AG-9306. The objective of these authors was to study case-
control associations in black newborns and white newborns.
Figure 3 - Factors that contribute to the RDS phenotype. Modified from
Haataja et al6
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A possible interaction was also analyzed between the exist-
ence of specific variants of SP-B and protective SP-A vari-
ants regarding susceptibility to RDS, aiming to determine
the existence of an increased or decreased risk for RDS.
The results indicate that different polymorphisms on
intron 4 of the SP-B gene are associated with different sub-
groups of RDS in white (deletion variant) and black (in-
sertion variant) individuals. In each racial group, the cor-
responding variant seemed to be a risk factor for white male
and black female individuals. In white individuals, the
genotypes of SP-A, 6A2, or 1A0, in the presence of a cer-
tain genotype of SP-B (9306 A/G) or intron 4 (del/*),
showed an increased risk for RDS. In black individuals,
however, the SP-A1, 6A3 protector genotype, in the pres-
ence of genotype SP-B 1580 (T/T), showed an increase pro-
tection against RDS, especially in individuals with ad-
vanced gestational ages.56
The polymorphism 1580 (C/T), present at the end of
exon 4, on nucleotide 1580, affects the amino acid 131,
altering the threonine amino acid (ACT) to isoleucine
(ATT). Such an alteration eliminates a potential site of
glycosylation and is associated with certain pulmonary
pathologies.44 WANG et al57confirmed the existence of an
N-linked glycosylation site at the terminal portion of SP-
B gene. The T allele of the polymorphism 1580 (C/T) does
not have the N-linked glycosylation site at the N-terminal
fragment, and it is considered a protector factor regarding
RDS, whereas the allelic variant C, which contains the rec-
ognition N glycosylation site of the fragment N-terminal,
is a risk factor for chronic obstructive pulmonary disease
(COPD) and ARDS.39,58
Martilla et al59 analyzed pairs of preterm twins of the
same sex of white race, where at least one of them pre-
sented RDS, and showed that genotypes specific for SP-A
and SP-B could influence the susceptibility to RDS. Re-
garding the protection against the development of the dis-
ease, it was evident both in the heterozygous C/T and ho-
mozygous T/T genotype. The authors suggested that the
genotype T/T seem to increase the protection in relation
to the disease, as was demonstrated with the black patients
with RDS by Floros et al.56
In a study conducted in Finland, the genotype C/C of
the polymorphism C/T 1580 seemed to constitute both a
risk factor for the alleles of SP-A for susceptibility to RDS
and a protective factor for the allele 6A3.60 Guo et al
showed that the allele C seemed to be associated with a
high risk of chronic obstructive pulmonary disease.58 Most
of studies available suggest that the genotype C/C seems
to be associated with a higher risk of pulmonary disease.
The polymorphism A/G on nucleotide 9306 is located
on region 3’UTR, just 4 nucleotides above the signaling
region TAATAAA. In vitro studies suggest that SP-A and
SP-B can interact functionally in a synergic way to reduce
alveolar tension.61 Both SP-A and SP-B are necessary for
the formation of tubular myelin, considered the structural
form of the surfactant. The levels of SP-A and SP-B and
of tubular myelin are decreased or absent in the lungs of
newborns with RDS.20,62,63 In a study by Kala et al, with a
control group (n = 86 whites and 12 blacks) and an RDS
group (n = 106 whites and 37 blacks) with gestational ages
varying from 24 weeks up to term, a positive synergic as-
sociation was observed between the allele 1 A0 and the
polymorphic variant of the intron 4 and RDS.36
In 2001 Floros et al conducted a case-control study with
preterm newborns with and without RDS.56 The authors
concluded that the genotype A/G of the polymorphism A/
G 9306 seems to be a susceptibility factor for RDS in in-
dividuals with gestational age greater than or equal to 33
weeks. The presence of specific alleles of SP-A and SP-B
in the same individual resulted in a considerable change
of the values of P or odds ratio, when compared to the val-
ues obtained with each genotype separately.
The polymorphism A/C – 18 is located on region
5’UTR, 11 nucleotides below the TATAAA box and 18
nucleotides to the left of the transcription initiation site,
which could have an impact on the beginning of mRNA
transcription. In the case-control study conducted by Floros
et al to verify the association of SP-A and SP-B
polymorphisms in white and black newborns with RDS, the
authors observed that, in black individuals, the frequency
of the genotype A/A of the polymorphism A/C – 18 was
higher (P = 0.04) when compared to genotype A/C. This
observation was found in preterm babies with RDS with
gestational ages between 28 and 31 weeks. However, the
number of individuals on this group was very small (con-
trol group, n = 4; RDS group, n = 19). No significant in-
teraction was observed between either of the two loci and
the alleles of SP-A.56
In 2003, Liu et al conducted a study to evaluate the
similarity of genetic markers among populations from 3
different ethnic groups (Caucasians, Blacks, and Hispanics),
with the objective of observing whether people from dif-
ferent races or ethnic groups could be grouped in linkage
analysis studies. The results showed that the allele and
genotype frequencies could be different among diverse eth-
nic groups, especially among ethnic groups of different
races.64
SP-B polymorphisms and other pathologies
In 2000 in Mexico, a group of researchers analyzed the
polymorphisms of SP-A, SP-B, and SP-D genes in a sam-
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ple of a Mexican population with chronic obstructive pul-
monary disease and concluded that the alleles of these pro-
teins could be useful for indicating subgroups that could
benefit from clinical treatment.58
An analysis of polymorphisms for SP-A, SP-B, and SP-
D genes was conducted in 52 patients with ARDS (idi-
opathic causes: pneumonia and others; exogenous causes:
surgery, trauma, and aspiration), 25 patients at risk of de-
veloping ARDS, and 46 healthy controls. The authors con-
cluded that the determination of polymorphisms on genes
that codify the surfactant proteins could be useful for the
study of pulmonary diseases, and that the polymorphism
C/T1580 could serve to differentiate subgroups of patients
with ARDS.39
Some studies suggest that allelic variations of SP-A and
SP-D could be associated with bronchiolitis caused by the
respiratory syncytial virus. The amino acids at position 223
of the SPA2 gene and 11 of SP-D gene could be involved
in the susceptibility to infections by the respiratory syncy-
tial virus, and they could be potential targets for prophy-
laxis and treatment with specific surfactant prepara-
tions.6,65,66
These studies indicate that the genetic variants of sur-
factant proteins could serve as valuable markers for the ge-
netic mapping of various pathologies, particularly RDS.
Additionally, racial differences have been described in other
studies as important risk factors for RDS. Taken together,
these studies support the possibility of a multifactorial and
multigenic etiology for RDS.
Despite the fact that various recent reports discuss the
complex etiopathogenesis of RDS from the molecular bi-
ology point of view, some questions remain unanswered,
such as the fact that some premature newborns present dis-
tinct clinical evolutions regarding the development of RDS,
as well as the different response of these newborn to the
maternal use of prophylactic corticoids.
New studies are necessary for a better understanding of
the specific mechanisms and the phenotypic consequences
of protector allelic variants or those that predispose to res-
piratory disease.
The determination of which polymorphisms and muta-
tions are, in fact, important in the pathogenesis of diseases
related to dysfunction of the surfactant proteins, together
with the possibility of conducting genotyping in high-risk
individuals, constitutes a new field of research that may in
the future facilitate more effective genetic counseling, and
result in the development of prophylactic and therapeutic
strategies that make a real impact on the management of
newborns having or at risk for RDS and other pulmonary
pathologies.
RESUMO
Priscila Pinheiro Ribeiro Lyra, Edna Maria de Albuquerque
Diniz. Síndrome da angustia respiratória aguda e proteinose
alveolar congênita. Clinics. 2007;62(2):181-90.
O surfactante pulmonar é uma substância composta por um
complexo lipoprotéico essencial para a função pulmonar
normal. As proteínas do surfactante têm importante papel
na estrutura, função e metabolismo do surfactante. São des-
critas quatro proteínas específicas denominadas surfactante
pulmonar-A, surfactante pulmonar-B, surfactante pulmonar-
C e surfactante pulmonar-D. Evidências clínicas,
epidemiológicas e bioquímicas sugerem que a etiologia da
síndrome do desconforto respiratório é multifatorial com
um componente genético significativo. Existem na litera-
tura algumas descrições sobre a presença de polimorfismos
e mutações em genes dos componentes do surfactante, par-
ticularmente no gene da surfactante pulmonar-B, os quais
parecem estar associados à síndrome do desconforto res-
piratório, síndrome da angustia respiratória aguda e
proteinose alveolar congênita. Diferenças individuais rela-
cionadas à síndrome do desconforto respiratórioe síndrome
da angustia respiratória aguda e à resposta dos pacientes
ao tratamento podem refletir diversidade fenotípica, devi-
do, parcialmente, à variação genética. O estudo das dife-
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renças entre as variantes alélicas dos genes das proteínas
do surfactante pode ajudar na compreensão das variabili-
dades individuais na susceptibilidade ao desenvolvimento
de várias doenças pulmonares. A determinação de quais
polimorfismos e mutações são, de fato, importantes na
patogênese das doenças relacionadas à disfunção das pro-
teínas do surfactante e a possibilidade da realização da
genotipagem em indivíduos de alto risco constitui um novo
campo de pesquisa, que pode permitir, futuramente, um
aconselhamento genético mais efetivo, resultando no de-
senvolvimento de estratégias profiláticas e terapêuticas que
representem um impacto real no manejo dos recém-nasci-
dos portadores da síndrome do desconforto respiratório e
outras patologias pulmonares.
UNITERMOS: Surfactante. Polimorfismos. Síndrome do
desconforto respiratório (SDR). Recém-nascido. Proteínas.
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